Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus
placebo in the treatment of patients suffering from smouldering or indolent systemic
mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal
symptomatic treatment.